Iridex Comments on Recent Stock Price Volatility
Iridex (NASDAQ: IRIX), a provider of laser-based medical systems for glaucoma and retinal diseases treatment, has addressed recent stock price volatility observed on March 13, 2025. The company explicitly stated there are no material developments or changes to its operating or financial condition that would explain the recent price and volume movements.
The company confirmed that no material adverse changes have occurred to its operating results, business, strategy, or prospects since their preliminary Q4 and full year 2024 results announcement on January 14, 2025. Final financial results will be discussed during a conference call scheduled for March 27, 2025, at 2:00pm PT.
Iridex (NASDAQ: IRIX), un fornitore di sistemi medici basati su laser per il trattamento del glaucoma e delle malattie retiniche, ha affrontato la recente volatilità del prezzo delle azioni osservata il 13 marzo 2025. L'azienda ha dichiarato esplicitamente che non ci sono sviluppi materiali o cambiamenti nella sua condizione operativa o finanziaria che possano spiegare i recenti movimenti di prezzo e volume.
L'azienda ha confermato che non si sono verificati cambiamenti negativi materiali nei suoi risultati operativi, nel business, nella strategia o nelle prospettive dall'annuncio dei risultati preliminari del quarto trimestre e dell'intero anno 2024 avvenuto il 14 gennaio 2025. I risultati finanziari finali saranno discussi durante una conference call programmata per il 27 marzo 2025, alle 14:00 PT.
Iridex (NASDAQ: IRIX), un proveedor de sistemas médicos basados en láser para el tratamiento del glaucoma y enfermedades retinianas, ha abordado la reciente volatilidad en el precio de las acciones observada el 13 de marzo de 2025. La compañía declaró explícitamente que no hay desarrollos materiales ni cambios en su condición operativa o financiera que expliquen los recientes movimientos de precio y volumen.
La empresa confirmó que no ha habido cambios adversos materiales en sus resultados operativos, negocio, estrategia o perspectivas desde el anuncio de los resultados preliminares del cuarto trimestre y del año completo 2024 el 14 de enero de 2025. Los resultados financieros finales se discutirán durante una conferencia telefónica programada para el 27 de marzo de 2025, a las 14:00 PT.
Iridex (NASDAQ: IRIX)는 녹내장 및 망막 질환 치료를 위한 레이저 기반 의료 시스템 공급업체로, 2025년 3월 13일에 관찰된 최근 주가 변동성에 대해 설명했습니다. 회사는 최근의 가격 및 거래량 변동을 설명할 수 있는 운영 또는 재무 상태의 중대한 변화가 없다고 명시적으로 밝혔습니다.
회사는 2025년 1월 14일에 발표된 2024년 4분기 및 연간 결과 발표 이후 운영 결과, 사업, 전략 또는 전망에 중대한 부정적 변화가 없었다고 확인했습니다. 최종 재무 결과는 2025년 3월 27일 오후 2시 PT에 예정된 컨퍼런스 콜에서 논의될 것입니다.
Iridex (NASDAQ: IRIX), un fournisseur de systèmes médicaux basés sur le laser pour le traitement du glaucome et des maladies rétiniennes, a abordé la récente volatilité du prix de l'action observée le 13 mars 2025. L'entreprise a déclaré explicitement qu'il n'y a pas eu de développements matériels ou de changements dans sa condition opérationnelle ou financière qui pourraient expliquer les récents mouvements de prix et de volume.
L'entreprise a confirmé qu'aucun changement défavorable matériel n'est survenu dans ses résultats opérationnels, son activité, sa stratégie ou ses perspectives depuis l'annonce de ses résultats préliminaires pour le quatrième trimestre et l'année complète 2024 le 14 janvier 2025. Les résultats financiers finaux seront discutés lors d'une conférence téléphonique prévue pour le 27 mars 2025 à 14h00 PT.
Iridex (NASDAQ: IRIX), ein Anbieter von laserbasierten Medizinsystemen zur Behandlung von Glaukom und Netzhauterkrankungen, hat die kürzliche Volatilität des Aktienkurses, die am 13. März 2025 beobachtet wurde, angesprochen. Das Unternehmen erklärte ausdrücklich, dass es keine wesentlichen Entwicklungen oder Änderungen in seinem Betriebs- oder Finanzzustand gibt, die die jüngsten Preis- und Volumenbewegungen erklären könnten.
Das Unternehmen bestätigte, dass seit der Bekanntgabe der vorläufigen Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 am 14. Januar 2025 keine wesentlichen nachteiligen Änderungen in seinen Betriebsergebnissen, Geschäften, Strategien oder Perspektiven aufgetreten sind. Die endgültigen finanziellen Ergebnisse werden während einer für den 27. März 2025 um 14:00 Uhr PT geplanten Telefonkonferenz erörtert.
- No adverse changes in operating results or business conditions since Q4 2024 preliminary results
- Unusual stock price volatility and trading volume without fundamental business cause
MOUNTAIN VIEW, Calif., March 14, 2025 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems and delivery devices for the treatment of glaucoma and retinal diseases, today commented on its recent stock price volatility.
The company is not aware of any material developments or changes to its operating or financial condition that precipitated the volume and price movements that occurred on March 13, 2025. There have been no material adverse changes to the company’s operating results, its business, strategy, or prospects since the company provided preliminary operating and financial results for the fourth quarter and full year 2024 on January 14, 2025.
Final fourth quarter and full year 2024 financial results will be released and discussed as previously announced on a conference call scheduled for 2:00pm PT on Thursday, March 27, 2025. Investors interested in listening to the conference call may do so by dialing +1-888-596-4144 and providing conference ID: 5685253. A live and recorded webcast on the “Event Calendar” page of the “Investors” section of the Company’s website at www.iridex.com
About Iridex Corporation
Iridex Corporation is a worldwide leader in developing, manufacturing, and marketing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. Iridex’s current product line is used for the treatment of glaucoma and diabetic macular edema (DME) and other retinal diseases. Iridex products are sold in the United States through a direct sales force and internationally primarily through a network of independent distributors into more than 100 countries. For further information, visit the Iridex website at www.iridex.com.
MicroPulse® is a registered trademark of Iridex Corporation, Inc. in the United States, Europe and other jurisdictions. © 2025 Iridex Corporation. All rights reserved.
Investor Relations Contact:
Philip Taylor
Gilmartin Group
investors@iridex.com
FAQ
What caused the stock price volatility in IRIX shares on March 13, 2025?
When will Iridex (IRIX) release its Q4 and full year 2024 financial results?
Has there been any change in Iridex's (IRIX) business strategy since January 2025?
How can investors join Iridex's (IRIX) upcoming earnings call?
